Short answer
Tango Therapeutics, Inc. (TNGX) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $54M (up 363.6% year over year) with net income of $16M.
Q3 2025 key financials · XBRL
- Revenue
- $54M
- +363.6% YoY · +1591.6% QoQ
- Net income
- $16M
- +154.5% YoY · +140.9% QoQ
- Operating margin
- 26.2%
- EPS (diluted)
- $0.14
- +151.9% YoY · +140.0% QoQ
Source: XBRL data from the Tango Therapeutics, Inc. (TNGX) Q3 2025 10-Q on SEC EDGAR. USD.
Tango Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added risk: Ongoing U.S. government shutdown since Sept 30, 2025 impacting FDA, SEC operations and potentially delaying regulatory reviews
- Most materially updated risk: Executive Orders 14273 and 14297 direct aggressive federal drug pricing policies, potentially affecting pricing, approvals, and market access
- Regulatory risk: Inflation Reduction Act and One Big Beautiful Bill Act modify Medicare drug price negotiation, restricting orphan drug exemptions and lowering potential prices earlier
- Operational risk: Geopolitical tensions including Russia-Ukraine conflict disrupt vendor chemistry work on pre-clinical candidates, risking supply chain continuity
- Financial risk: Tax law changes under OBBB impact R&D capitalization and amortization requirements effective 2025, potentially increasing cash flow burdens and effective tax rate
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tango Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.